# A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

> **NCT02586987** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 58 (actual)

## Conditions studied

- Lung Cancer
- Melanoma
- Head and Neck Carcinoma
- Gastroesophageal Cancer
- Breast Cancer
- Pancreatic Adenocarcinoma
- Colorectal Cancer
- Biliary Tract Cancer

## Interventions

- **DRUG:** Selumetinib
- **DRUG:** MEDI4736
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT02586987
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-28
- **Primary completion:** 2018-07-25
- **Final completion:** 2019-09-20
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2019-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02586987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02586987, "A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02586987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*